Is the heterochromatin checkpoint a useful anti-cancer drug target? (2008-2009)
Abstract
Histone deacetylase inhibitors are a new class of anti-cancer drug showing great clinical promise. By understanding the mechanism of action of these drugs we hope to improve the clinical efficacy of these drugs, and to identify new targets for drugs that utilize the same cancer specific defects that provide the therapeutic benefits of the deacetylase inhibitors.
